


WE CLAIM:

1. A method for treating Huntington's disease comprising administering an effective amount of a NAALADase inhibitor to a mammal in need of such treatment.

5

2. The method of claim 1, wherein the NAALADase inhibitor is an acid containing a metal binding group.


3. The method of claim 1, wherein the NAALADase
10 inhibitor is a compound of formula I




I

or an enantiomer or a pharmaceutically acceptable equivalent of said compound, wherein:


15 X is a moiety of formula II, III or IV



II



III



IV ;

Z is SH, SO₃H, SO₂H, SOH, SO(NH)R⁴ or S(NHR⁴)₂R⁵;

B is N or CR⁶;

A is O, S, CR⁷R⁸ or (CR⁷R⁸)_mS;

5 m and n are independently 0, 1, 2, 3 or 4;

10 R, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are independently hydrogen, C₁-C₉ alkyl, C₂-C₉ alkenyl, C₃-C₈ cycloalkyl, C₅-C₇ cycloalkenyl, Ar, hydroxy, carboxy, carbonyl, amino, cyano, isocyano, nitro, sulfonyl, sulfoxy, thio, thiocarbonyl, thiocyno, formanilido, thioformamido, sulfhydryl, halo, haloalkyl, trifluoromethyl or oxy, wherein said alkyl, alkenyl, cycloalkyl and cycloalkenyl are independently unsubstituted or substituted with one or more substituent(s); and

Ar is a carbocyclic or heterocyclic moiety, which is unsubstituted or substituted with one or more substituent(s);

provided that when X is a moiety of formula II and A is O, then n is 2, 3 or 4; when X is a moiety of formula II and A is S, then n is 2, 3 or 4; and when X is a moiety of formula II and A is $(CR^7R^8)_mS$, then n is 0, 2, 3 or 4.

4. The method of claim 3, wherein:

10 X is a moiety of formula II;

n is 0, 1, 2 or 3;

Z is SH, SO_3H , SO_2H , SOH or $S(NHR^4)_2R^5$; and

A is O, S or CR^7R^8 .

15 5. The method of claim 4, wherein Z is SH.

6. The method of claim 5, wherein R is $-(CH_2)_2COOH$.

20 7. The method of claim 1, wherein the NAALADase inhibitor is selected from:

2-(2-sulfanylethyl)pentanedioic acid;


3-(2-sulfanylethyl)-1,3,5-pentanetricarboxylic acid;

2-(2-sulfanylpropyl)pentanedioic acid;

2-(2-sulfanylbutyl)pentanedioic acid;

- 2-(2-sulfanyl-2-phenylethyl)pentanedioic acid;
 2-(2-sulfanylhexyl)pentanedioic acid;
 2-(2-sulfanyl-1-methylethyl)pentanedioic acid;
 2-[1-(sulfanylmethyl)propyl]pentanedioic acid;
 5 2-(3-sulfanylpentyl)pentanedioic acid;
 2-(3-sulfanylpropyl)pentanedioic acid;
 2-(3-sulfanyl-2-methylpropyl)pentanedioic acid;
 2-(3-sulfanyl-2-phenylpropyl)pentanedioic acid;
 2-(3-sulfanylbutyl)pentanedioic acid;
 10 2-[3-sulfanyl-2-(phenylmethyl)propyl]pentanedioic
 acid;
 2-[2-(sulfanylmethyl)butyl]pentanedioic acid;
 2-[2-(sulfanylmethyl)pentyl]pentanedioic acid;
 2-(3-sulfanyl-4-methylpentyl)pentanedioic acid; and
 15 enantiomers and pharmaceutically acceptable
 equivalents.

8. The method of claim 1, wherein the NAALADase inhibitor is a compound of formula V



V

or an enantiomer or a pharmaceutically acceptable equivalent of said compound, wherein:

X^1 is $-W-Z^1$;


5 W is a bond or a linking group;

Z^1 is a terminal group; and

Y^1 is $-COOH$ oriented *meta* or *para* relative to C-1.

9. The method of claim 8, wherein:

10 X^1 is $-(CR^9R^{10})_nNH(CR^{11}R^{12})_mCOOH$, $-PO(OH)OR^{14}$,
 $-(CR^9R^{10})_nP(O)(OH)R^{14}$, $-NH-(CR^{11}R^{12})_m$ -heteroaryl,
 $-NH(P(O)(R^{15})OH)$, $-(CR^9R^{10})_nNH(P(O)(OH)R^{15})$, $-CON(R^{14})(OH)$,
 $-(CR^9R^{10})_nCON(R^{14})(OH)$, $-(CR^9R^{10})_nSH$, $-O(CR^{11}R^{12})_mSH$,
 $-SO_2NH$ -aryl, $-N(C=O)-CH_2(C=O)$ -aryl, $-SO_2NH$ -aryl,
 15 $-N(C=O)-CH_2(C=O)$ -aryl or $-O$ -aryl, wherein aryl in $-O$ -aryl
 is substituted by at least one of nitro, carboxy or



wherein X^1 is oriented *meta* or *para* relative to C-1;

20 Ar is a carbocyclic or heterocyclic moiety, which is
 unsubstituted or substituted with one or more
 substituent(s);

m and n are independently 1-3, provided that when X^1
 is $-O(CR^{11}R^{12})_mSH$, then m is 2 or 3;

25 R^9 , R^{10} , R^{11} , R^{12} , R^{14} , R^{15} and R^{17} are independently
 hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl,

heteroaryl, carbocycle, heterocycle, halo, hydroxy, sulfhydryl, nitro, amino or C₁-C₆ alkoxy, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, heterocycle and alkoxy are independently unsubstituted or
5 substituted with one or more substituent(s); and

Y¹ is -COOH oriented *meta* or *para* relative to C-1.

10. The method of claim 8, wherein X¹ is oriented *ortho* relative to C-1, and Y¹ is oriented *para* relative to
10 X¹ and *meta* relative to C-1.

11. The method of claim 10, wherein W is a bond, and Z¹ is -CO₂H, -OH, -NO₂, -C(O)(NHR¹⁵), -SR¹⁵, -COR¹⁵ or -NH(CH₂R¹⁵), and R¹⁵ is an aryl or a heteroaryl wherein said
15 aryl and heteroaryl are independently unsubstituted or substituted with one or more alkyl, nitro or carboxy group(s).

12. The method of claim 10, wherein W is -(CH₂)_n- and
20 n is 1-3, and Z¹ is -SH.

13. The method of claim 8, wherein the linking groups are selected from divalent hydrocarbon chains, ethers, sulfides and amines, wherein the hydrocarbon
25 chains, whether alone or part of ethers, sulfides, and/or amines, may be saturated or unsaturated, straight or branched, open or closed, unsubstituted or substituted with one or more substituents.

14. The method of claim 13, wherein the one or more substituents are independently selected from C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, phenoxy, benzyloxy, hydroxy, carboxy, carbamido, carbamoyl, carbamyl, carbonyl, carbozoyl, amino, hydroxyamino, formamido, formyl, guanyl, cyano, cyanoamino, isocyano, isocyanato, diazo, azido, hydrazino, triazano, nitro, nitroso, isonitroso, nitrosamino, imino, nitrilo, isonitrilo, nitrosimino, oxo, C₁-C₆ alkylthio, sulfamino, sulfamoyl, sulfeno, sulfhydryl, sulfinyl, sulfo, sulfonyl, sulfoxy, thiocarboxy, thiocyano, isothiocyano, thioformamido, halo, haloalkyl, chlorosyl, chloryl, perchloryl, trifluoromethyl, iodosyl, iodyl, phosphino, phosphinyl, phospho, phosphono, arsino, selanyl, diselanyl, siloxy, silyl and silylene groups.

15

15. The method of claim 8, wherein W is a bond, $-(CR^9R^{10})_n-$, $-(CR^9R^{10})_nO(CR^{11}R^{12})_m-$, $-(CR^9R^{10})_nS(CR^{11}R^{12})_m-$ or $-(CR^9R^{10})_nNR^{13}(CR^{11}R^{12})_m-$, wherein m and n are independently 0-9, and R⁹, R¹⁰, R¹¹, R¹² and R¹³ are independently hydrogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₆-C₁₄ aryl, heteroaryl, C₆-C₁₄ carbocycle, heterocycle, halo, hydroxy, sulfhydryl, nitro, amino or C₁-C₆ alkoxy, and said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, heterocycle and alkoxy are independently unsubstituted or substituted with one or more substituents.

30

16. The method of claim 15, wherein R⁹, R¹⁰, R¹¹, R¹² and R¹³ are each hydrogen and the total number of carbon atoms in W is 2-6.


17. The method of claim 8, wherein Z¹ is a metal binding group.

18. The method of claim 8, wherein Z^1 is $-\text{COOH}$,
 $-\text{COR}^{14}$, $-\text{OR}^{14}$, $-\text{CF}_3$, $-\text{CN}$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{NO}$, $-\text{NO}_2$,
 $-\text{C}(\text{O})(\text{NR}^{14}\text{OR}^{15})$, $-\text{C}(\text{O})(\text{NR}^{14}\text{PO}_3\text{H}_2)$, $-\text{C}(\text{O})(\text{NR}^{14}\text{R}^{15})$, $=\text{NOH}$,
5 $-\text{NR}^{14}(\text{P}(\text{O})(\text{R}^{15})\text{OH})$, $=\text{NR}^{14}$, $-\text{N}=\text{NR}^{14}$, $-\text{N}(\text{R}^{14})\text{CN}$,
 $-\text{NR}^{14}(\text{CR}^{15}\text{R}^{16})_p\text{COOH}$, $-\text{NR}^{14}(\text{CO})\text{NR}^{15}\text{R}^{16}$, $-\text{NR}^{14}(\text{COOR}^{15})$, $-\text{NR}^{14}(\text{CO})\text{R}^{15}$,
 $-\text{NR}^{14}(\text{OR}^{15})$, $-\text{NR}^{14}\text{R}^{15}$, $-\text{NR}^{14}(\text{SO}_2\text{R}^{15})$, $-\text{O}(\text{CO})\text{R}^{14}$, $-\text{OR}^{14}$, $-\text{SO}_2(\text{OR}^{14})$,
 $-\text{SO}_2(\text{NR}^{14}\text{R}^{15})$, $-\text{SO}_2\text{R}^{14}$, $-\text{SO}_3\text{R}^{14}$, $-\text{SNR}^{14}(\text{OR}^{15})$, $-\text{S}(\text{NR}^{14}\text{R}^{15})$, $-\text{SR}^{14}$,
 $-\text{SSR}^{14}$, $-\text{P}(\text{O})(\text{OH})\text{OR}^{14}$, $-\text{P}(\text{O})(\text{OH})\text{R}^{14}$ or $-\text{PR}^{14}\text{R}^{15}$, wherein p is
10 3-6, and R^{14} , R^{15} and R^{16} are independently hydrogen, C_1 - C_9
alkyl, C_2 - C_9 alkenyl, C_2 - C_9 alkynyl, C_6 - C_{14} aryl, heteroaryl,
 C_6 - C_{14} carbocycle, heterocycle, halo, hydroxy, sulfhydryl,
nitro, amino or C_1 - C_9 alkoxy, and said alkyl, alkenyl,
15 alkynyl, aryl, heteroaryl, carbocycle, heterocycle and
alkoxy are independently unsubstituted or substituted with
one or more substituents.

19. The method of claim 18, wherein Z^1 is
 $-\text{NH}(\text{CR}^{15}\text{R}^{16})_p\text{COOH}$, $-\text{PO}(\text{OH})\text{OR}^{14}$, $-\text{PO}(\text{OH})\text{R}^{14}$, $-\text{NR}^{14}(\text{P}(\text{O})(\text{R}^{15})\text{OH})$,
20 $-\text{CON}(\text{R}^{14})(\text{OH})$ or $-\text{SH}$.

20. The method of claim 8, wherein

X^1 is $-(\text{CR}^9\text{R}^{10})_n\text{NH}(\text{CR}^{11}\text{R}^{12})_m\text{COOH}$, $-\text{PO}(\text{OH})\text{OR}^{14}$,
 $-(\text{CR}^9\text{R}^{10})_n\text{P}(\text{O})(\text{OH})\text{R}^{14}$, $-\text{NH}-(\text{CR}^{11}\text{R}^{12})_m\text{-heteroaryl}$,
25 $-\text{NH}(\text{P}(\text{O})(\text{R}^{15})\text{OH})$, $-(\text{CR}^9\text{R}^{10})_n\text{NH}(\text{P}(\text{O})(\text{OH})\text{R}^{15})$, $-\text{CON}(\text{R}^{14})(\text{OH})$,
 $-(\text{CR}^9\text{R}^{10})_n\text{CON}(\text{R}^{14})(\text{OH})$, $-(\text{CR}^9\text{R}^{10})_n\text{SH}$, $-\text{O}(\text{CR}^{11}\text{R}^{12})_m\text{SH}$,
 $-\text{SO}_2\text{NH-aryl}$, $-\text{N}(\text{C}=\text{O})-\text{CH}_2(\text{C}=\text{O})\text{-aryl}$, $-\text{SO}_2\text{NH-aryl}$,
 $-\text{N}(\text{C}=\text{O})-\text{CH}_2(\text{C}=\text{O})\text{-aryl}$, or $-\text{O-aryl}$ wherein aryl in $-\text{O-aryl}$
is substituted by at least one of nitro, carboxy or
30



wherein X^1 is oriented *meta* or *para* relative to C-1;

Ar is a carbocyclic or heterocyclic moiety, which is unsubstituted or substituted with one or more
 5 substituent(s);

m and n are independently 1-3, provided that when X^1 is $-O(CR^{11}R^{12})_mSH$, then m is 2 or 3;

R^9 , R^{10} , R^{11} , R^{12} , R^{14} , R^{15} and R^{17} are independently hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl,
 10 heteroaryl, carbocycle, heterocycle, halo, hydroxy, sulfhydryl, nitro, amino or C_1-C_6 alkoxy, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, heterocycle and alkoxy are independently unsubstituted or substituted with one or more substituents; and

15 Y^1 is $-COOH$ oriented *meta* or *para* relative to C-1.

21. The method of claim 20, wherein X^1 is $-PO(OH)OR^{14}$ or $-(CR^9R^{10})_nP(O)(OH)OR^{14}$, and R^{14} is not H or methyl.

20 22. The method of claim 20, wherein X^1 is $-NH(P(O)(R^{15})OH$ or $-(CR^9R^{10})_nNH(P(O)(OH)R^{15})$, and R^{15} is not benzyl unsubstituted or substituted with amino.

23. The method of claim 20, wherein X^1 is
 25 $-CON(R^{14})(OH)$, and R^{14} is not H or methyl.

24. The method of claim 8, wherein X^1 is oriented meta relative to C-1, and Y^1 is oriented ortho relative to X^1 and para relative to C-1.

5

25. The method of claim 24, wherein W is a bond, $-(CH_2)_n-NH-(CH_2)_m-$ or $-(CH_2)_n-$; m is 1-3; n is 0-3; and Z^1 is $-CO_2H$, $-NO_2$, $-NH_2$, $-SO_3H$, halo, C_5-C_6 heteroaryl, carboxyphenylthio, or mono- or di-carboxyphenylsulfonyl.

10

26. The method of claim 8, wherein X^1 is oriented meta relative to C-1, and Y^1 is oriented meta relative to X^1 and meta relative to C-1.

15

27. The method of claim 26, wherein W is a bond, $-(CH_2)_n-$ or $-O(CH_2)_m-$ and m and n are independently 0-3, and Z^1 is $-SO_3H$, $-NO_2$, $-NH_2$, $-CO_2H$, $-OH$, $-PO_3H$, $-CO(NHOH)$, $-SH$ or an optionally substituted phenyl wherein one or more substituents are selected from nitro and carboxy.

20

28. The method of claim 26, wherein W is $-(CH_2)_nNH(CH_2)_m-$ and m and n are independently 0-3, and Z^1 is $-CO_2H$ or C_5-C_6 heteroaryl.

25

29. The method of claim 26, wherein W is $-(CH_2)_n-$ wherein n is 0-3, and (a) Z^1 is a heteroaryl that is unsubstituted or substituted with an aryl that is unsubstituted or substituted with one or more C_1-C_3 alkyl, halo, nitro or hydroxy group(s), or (b) Z^1 is $-SO_2(NHR^{16})$ or

-NH(COR¹⁶), wherein R¹⁶ is an optionally substituted C₁-C₃ alkyl wherein one or more substituents are selected from oxo, phenyl, and substituted phenyl; and R¹⁶ may also be selected from an aryl that is unsubstituted or substituted
5 with one or more nitro, amino, halo or hydroxy group(s).

30. The method of claim 1, wherein the NAALADase inhibitor is selected from:

2-[(4-carboxyphenyl)sulfonyl]-1,4-benzene-
10 dicarboxylic acid;

2-[(2,5-dicarboxyphenyl)sulfonyl]-1,4-benzene-
dicarboxylic acid;

1,2,4-benzenetricarboxylic acid;

2-[(2-carboxyphenyl)thio]-1,4-benzenedicarboxylic
15 acid;

2-nitro-1,4-benzenedicarboxylic acid;

2-bromo-1,4-benzenedicarboxylic acid;

2-amino-1,4-benzenedicarboxylic acid;

2-sulfoterephthalic acid, monosodium salt;

20 2-carboxymethyl-1,4-benzenedicarboxylic acid;

2-[(2-furanylmethyl)-amino]-1,4-benzenedicarboxylic
acid;

2-[(carboxymethyl)amino]-1,4-benzenedicarboxylic
acid;

25 4-(4-nitrobenzoyl)-1,3-benzenedicarboxylic acid;

- 4-[4-(2,4-dicarboxybenzoyl)phenoxy]-1,2-benzene-dicarboxylic acid;
- 4-[4-(2,4-dicarboxybenzoyl)phenoxy]-1,3-benzene-dicarboxylic acid;
- 5 4-[[(2,4,6-trimethylphenyl) amino] carbonyl]-1,3-benzenedicarboxylic acid;
- 4-nitro-1,3-benzenedicarboxylic acid;
- 4-[(1-naphthalenylamino)-carbonyl]-1,3-benzene-dicarboxylic acid;
- 10 1,2,4-benzenetricarboxylic acid;
- 4-[(2-carboxyphenyl)thio]-1,3-benzenedicarboxylic acid;
- 4-[3-[[3-(2,4-dicarboxyphenoxy)propyl]dithio]propoxy]-1,3-benzenedicarboxylic acid;
- 15 4-hydroxy-1,3-benzenedicarboxylic acid;
- 4-[(2-furanylmethyl) amino]-1,3-benzenedicarboxylic acid;
- 4-(2-mercaptoethyl)-1,3-benzenedicarboxylic acid;
- 5-[4,5-dihydro-5-(4-hydroxyphenyl)-3-phenyl-1H-pyrazol-1-yl]-1,3-benzenedicarboxylic acid;
- 20 5-(4,5-dihydro-3-methyl-5-phenyl-1H-pyrazol-1-yl)-1,3-benzenedicarboxylic acid;
- 5-[[(4-chloro-3-nitrophenyl) amino] sulfonyl]-1,3-benzenedicarboxylic acid;
- 25 5-[[[4-chloro-3-[[3-(2-methoxyphenyl)-1,3-dioxopropyl] amino] phenyl] amino] sulfonyl-1,3-benzenedicarboxylic acid;

5-[[3-[4-(acetylamino)phenyl]-1,3-dioxopropyl]amino]-
1,3-benzenedicarboxylic acid;

5-acetylamino-1,3-benzenedicarboxylic acid;

5-[[[(1-hydroxy-2-naphthalenyl) carbonyl]-methylamino]-
1,3-benzenedicarboxylic acid;

5-(4-carboxy-2-nitrophenoxy)-1,3-benzenedicarboxylic
acid;

5-sulfo-1,3-benzenedicarboxylic acid;

5-nitro-1,3-benzenedicarboxylic acid;

5-amino-1,3-benzenedicarboxylic acid;

1,3,5-benzenetricarboxylic acid;

5-[[[(3-amino-4-chlorophenyl) amino] sulfonyl]-1,3-
benzenedicarboxylic acid;

5-(3-mercaptopropoxy)-1,3-benzenedicarboxylic acid;

5-hydroxy-1,3-benzenedicarboxylic acid;

5-(2-mercaptoethoxy)-1,3-benzenedicarboxylic acid;

5-[(hydroxyamino) carbonyl]-1,3-benzenedicarboxylic
acid;

5-phosphono-1,3-benzenedicarboxylic acid;

5-mercaptomethyl-1,3-benzenedicarboxylic acid;

5-phosphonomethyl-1,3-benzenedicarboxylic acid;

5-[[[(carboxymethyl) amino]-methyl]-1,3-benzene-
dicarboxylic acid;

5-[(carboxymethyl) amino]-1,3-benzenedicarboxylic
acid;

5-[[(2-furanylmethyl) amino] -methyl] -1,3-benzene-dicarboxylic acid;

5- [2- (hydroxyamino) -2-oxoethyl] -1,3-benzene-dicarboxylic acid;

5 5- (2-mercaptoethyl) -1,3-benzenedicarboxylic acid; and
 enantiomers and pharmaceutically acceptable
 equivalents.

31. A method for treating Huntington's disease
10 comprising administering an effective amount of a compound
selected from:

2- [(4-carboxyphenyl) sulfonyl] -1,4-benzene-dicarboxylic acid;

15 2- [(2,5-dicarboxyphenyl) sulfonyl] -1,4-benzene-dicarboxylic acid;

1,2,4-benzenetricarboxylic acid;

2- [(2-carboxyphenyl) thio] -1,4-benzenedicarboxylic acid;

2-nitro-1,4-benzenedicarboxylic acid;

20 2-bromo-1,4-benzenedicarboxylic acid;

2-amino-1,4-benzenedicarboxylic acid;

2-sulfoterephthalic acid, monosodium salt;

2-carboxymethyl-1,4-benzenedicarboxylic acid;

25 2- [(2-furanylmethyl) -amino] -1,4-benzenedicarboxylic acid;

- 2-[(carboxymethyl) amino]-1,4-benzenedicarboxylic acid;
- 4-(4-nitrobenzoyl)-1,3-benzenedicarboxylic acid;
- 4-[4-(2,4-dicarboxybenzoyl)phenoxy]-1,2-benzene-
5 dicarboxylic acid;
- 4-[[(2,4,6-trimethylphenyl) amino] carbonyl]-1,3-benzenedicarboxylic acid;
- 4-nitro-1,3-benzenedicarboxylic acid;
- 4-[(1-naphthalenylamino)-carbonyl]-1,3-benzene-
10 dicarboxylic acid;
- 1,2,4-benzenetricarboxylic acid;
- 4-[(2-carboxyphenyl)thio]-1,3-benzenedicarboxylic acid;
- 4-[3-[[3-(2,4-dicarboxyphenoxy)propyl]dithio]-
15 propoxy]-1,3-benzenedicarboxylic acid;
- 4-hydroxy-1,3-benzenedicarboxylic acid;
- 4-[(2-furanylmethyl) amino]-1,3-benzenedicarboxylic acid;
- 4-(2-mercaptoethyl)-1,3-benzenedicarboxylic acid;
- 20 5-[4,5-dihydro-5-(4-hydroxyphenyl)-3-phenyl-1H-pyrazol-1-yl]-1,3-benzenedicarboxylic acid;
- 5-(4,5-dihydro-3-methyl-5-phenyl-1H-pyrazol-1-yl)-1,3-benzenedicarboxylic acid;
- 25 5-[[(4-chloro-3-nitrophenyl) amino] sulfonyl]-1,3-benzenedicarboxylic acid;

5-[[[4-chloro-3-[[3-(2-methoxyphenyl)-1,3-dioxopropyl]amino]phenyl]amino]sulfonyl]-1,3-benzenedicarboxylic acid;

5-[[3-[4-(acetylamino)phenyl]-1,3-dioxopropyl]amino]-
5 1,3-benzenedicarboxylic acid;

5-acetylamino-1,3-benzenedicarboxylic acid;

5-[[[(1-hydroxy-2-naphthalenyl)carbonyl]-methylamino]-
1,3-benzenedicarboxylic acid;

5-(4-carboxy-2-nitrophenoxy)-1,3-benzenedicarboxylic
10 acid;

5-sulfo-1,3-benzenedicarboxylic acid;

5-nitro-1,3-benzenedicarboxylic acid;

5-amino-1,3-benzenedicarboxylic acid;

1,3,5-benzenetricarboxylic acid;

15 5-[[[(3-amino-4-chlorophenyl)amino]sulfonyl]-1,3-benzenedicarboxylic acid;

5-(3-mercaptopropoxy)-1,3-benzenedicarboxylic acid;

5-hydroxy-1,3-benzenedicarboxylic acid;

5-(2-mercaptoethoxy)-1,3-benzenedicarboxylic acid;

20 5-[(hydroxyamino)carbonyl]-1,3-benzenedicarboxylic acid;

5-phosphono-1,3-benzenedicarboxylic acid;

5-mercaptomethyl-1,3-benzenedicarboxylic acid;

5-phosphonomethyl-1,3-benzenedicarboxylic acid;

5- [[(carboxymethyl) amino] -methyl] -1,3-benzene-
dicarboxylic acid;

5- [(carboxymethyl) amino] -1,3-benzenedicarboxylic
acid;

5 5- [[(2-furanylmethyl) amino] -methyl] -1,3-benzene-
dicarboxylic acid;

5- [2- (hydroxyamino) -2-oxoethyl] -1,3-benzene-
dicarboxylic acid;

5- (2-mercaptoethyl) -1,3-benzenedicarboxylic acid; and
10 enantiomers and pharmaceutically acceptable
equivalents.

32. A pharmaceutical composition comprising:

(i) an effective amount of a NAALADase
15 inhibitor for treating Huntington's disease; and

(ii) a pharmaceutically acceptable carrier.

33. A method of making a pharmaceutical composition
comprising mixing an effective amount of a NAALADase
20 inhibitor for treating Huntington's disease and a
pharmaceutically acceptable carrier.